{"id":65227,"date":"2026-05-13T23:39:07","date_gmt":"2026-05-13T15:39:07","guid":{"rendered":"https:\/\/flcube.com\/?p=65227"},"modified":"2026-05-13T23:39:08","modified_gmt":"2026-05-13T15:39:08","slug":"shanghai-immunocan-biotech-secures-rmb-250m-series-a-led-by-vivo-capital-to-advance-gene-edited-antibody-discovery-platforms","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65227","title":{"rendered":"Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms"},"content":{"rendered":"\n<p><strong>Shanghai Immunocan Biotech Co., Ltd.<\/strong> announced the successful completion of a <strong>RMB 250 million<\/strong> (USD 36.8 million) <strong>Series A financing round<\/strong> led by <strong>Vivo Capital<\/strong>, with participation from <strong>Gold Mine Multi Family Office<\/strong> and existing shareholders <strong>Kingray Capital<\/strong> and <strong>TigerYeah Capital<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financing-overview\">Financing Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shanghai Immunocan Biotech Co., Ltd.<\/td><\/tr><tr><td><strong>Financing Round<\/strong><\/td><td>Series A<\/td><\/tr><tr><td><strong>Total Amount<\/strong><\/td><td>RMB 250 million (USD 36.8 million)<\/td><\/tr><tr><td><strong>Lead Investor<\/strong><\/td><td>Vivo Capital<\/td><\/tr><tr><td><strong>Participating Investors<\/strong><\/td><td>Gold Mine Multi Family Office, Kingray Capital, TigerYeah Capital<\/td><\/tr><tr><td><strong>Primary Focus<\/strong><\/td><td>Next-generation antibody discovery platforms based on gene editing technology<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fund-allocation-strategy\">Fund Allocation Strategy<\/h2>\n\n\n\n<p>Proceeds will be strategically deployed across multiple platform development initiatives:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Initiative<\/th><th>Strategic Objective<\/th><\/tr><\/thead><tbody><tr><td><strong>Gene-edited animal platforms<\/strong><\/td><td>Accelerate continuous R&amp;D of proprietary transgenic models<\/td><\/tr><tr><td><strong>Fully human antibody rabbit platform<\/strong><\/td><td>Advance commercialization of established rabbit-derived antibody technology<\/td><\/tr><tr><td><strong>AI-driven antibody drug screening platform<\/strong><\/td><td>Establish machine learning-enhanced discovery capabilities<\/td><\/tr><tr><td><strong>Scaffold antibodies for complex targets<\/strong><\/td><td>Develop novel binding formats for challenging epitopes<\/td><\/tr><tr><td><strong>General corporate operations &amp; team expansion<\/strong><\/td><td>Support infrastructure growth and talent acquisition<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-proprietary-technology-portfolio\">Proprietary Technology Portfolio<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-masirt-platform-innovation\">MASIRT Platform Innovation<\/h3>\n\n\n\n<p>The company&#8217;s core <strong>Massive-fragment Across Species In situ Replacement Technology (MASIRT)<\/strong> represents a breakthrough in gene editing capabilities:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Technical Feature<\/th><th>Competitive Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Linear artificial chromosome delivery<\/strong><\/td><td>Significantly enhanced gene fragment loading capacity<\/td><\/tr><tr><td><strong>Megabase-scale DNA replacement<\/strong><\/td><td>Single-operation large-fragment editing capability<\/td><\/tr><tr><td><strong>Reduced editing cycles<\/strong><\/td><td>Drastic improvement in development timeline efficiency<\/td><\/tr><tr><td><strong>Species barrier elimination<\/strong><\/td><td>Successful cross-species application without limitations<\/td><\/tr><tr><td><strong>Multi-species validation<\/strong><\/td><td>Proven functionality across diverse animal models<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-diversified-antibody-discovery-platforms\">Diversified Antibody Discovery Platforms<\/h3>\n\n\n\n<p>Immunocan Bio has developed a comprehensive portfolio of proprietary platforms:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Platform<\/th><th>Unique Characteristics<\/th><th>IP Protection<\/th><\/tr><\/thead><tbody><tr><td><strong>Fully human mouse platform<\/strong><\/td><td>Established transgenic mouse model<\/td><td>China, Europe, USA, Japan<\/td><\/tr><tr><td><strong>Fully human rabbit platform<\/strong><\/td><td>Enhanced diversity and affinity maturation<\/td><td>China, Europe, USA, Japan<\/td><\/tr><tr><td><strong>Rabbit-derived single heavy-chain antibody platform<\/strong><\/td><td>Simplified format with improved tissue penetration<\/td><td>China, Europe, USA, Japan<\/td><\/tr><tr><td><strong>ImmuAlpaca (alpaca-mouse) platform<\/strong><\/td><td>Novel hybrid species combining advantageous traits<\/td><td>China, Europe, USA, Japan<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-market-positioning\">Strategic Market Positioning<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-next-generation-antibody-discovery\">Next-Generation Antibody Discovery<\/h3>\n\n\n\n<p>The company addresses critical industry challenges in therapeutic antibody development:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target complexity<\/strong>: Scaffold antibodies designed for difficult-to-drug targets<\/li>\n\n\n\n<li><strong>Diversity limitations<\/strong>: Multi-species platforms provide broader antibody repertoire<\/li>\n\n\n\n<li><strong>Development efficiency<\/strong>: MASIRT technology reduces timeline from target to lead candidate<\/li>\n\n\n\n<li><strong>Format innovation<\/strong>: Single-domain and conventional antibodies from same platform family<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-differentiation\">Competitive Differentiation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Integrated approach<\/strong>: Combines gene editing, multi-species platforms, and AI-driven screening<\/li>\n\n\n\n<li><strong>IP moat<\/strong>: Comprehensive patent protection across major pharmaceutical markets<\/li>\n\n\n\n<li><strong>Platform breadth<\/strong>: Unusual combination of mouse, rabbit, and alpaca-derived technologies<\/li>\n\n\n\n<li><strong>Technical leadership<\/strong>: MASIRT represents significant advancement over conventional gene editing<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-context-amp-investment-rationale\">Industry Context &amp; Investment Rationale<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-antibody-discovery-market-evolution\">Antibody Discovery Market Evolution<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform competition<\/strong>: Intense race among biotech companies to develop superior discovery technologies<\/li>\n\n\n\n<li><strong>Big pharma demand<\/strong>: Major pharmaceutical companies increasingly outsourcing antibody discovery to specialized platforms<\/li>\n\n\n\n<li><strong>Technical innovation<\/strong>: Shift toward gene-edited animals with enhanced human-like immune systems<\/li>\n\n\n\n<li><strong>AI integration<\/strong>: Growing adoption of machine learning in antibody optimization and screening<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-chinese-biotech-ecosystem\">Chinese Biotech Ecosystem<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform company emergence<\/strong>: China developing sophisticated biologics discovery infrastructure<\/li>\n\n\n\n<li><strong>International competitiveness<\/strong>: Chinese platforms increasingly competitive with Western counterparts<\/li>\n\n\n\n<li><strong>Investment momentum<\/strong>: Strong venture capital interest in next-generation biologics technologies<\/li>\n\n\n\n<li><strong>Global ambition<\/strong>: Companies like Immunocan targeting international partnerships and licensing deals<\/li>\n<\/ul>\n\n\n\n<p>The Series A financing validates Immunocan&#8217;s <strong>integrated platform strategy<\/strong> and positions the company to become a leading global provider of next-generation antibody discovery capabilities, combining cutting-edge gene editing with multi-species diversity and AI-enhanced screening.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Immunocan Biotech Co., Ltd. announced the successful completion of a RMB 250 million (USD&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2719],"class_list":["post-65227","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-immunocan-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Immunocan Biotech Co., Ltd. announced the successful completion of a RMB 250 million (USD 36.8 million) Series A financing round led by Vivo Capital, with participation from Gold Mine Multi Family Office and existing shareholders Kingray Capital and TigerYeah Capital.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65227\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms\" \/>\n<meta property=\"og:description\" content=\"Shanghai Immunocan Biotech Co., Ltd. announced the successful completion of a RMB 250 million (USD 36.8 million) Series A financing round led by Vivo Capital, with participation from Gold Mine Multi Family Office and existing shareholders Kingray Capital and TigerYeah Capital.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65227\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T15:39:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-13T15:39:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65227#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65227\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms\",\"datePublished\":\"2026-05-13T15:39:07+00:00\",\"dateModified\":\"2026-05-13T15:39:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65227\"},\"wordCount\":552,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Immunocan Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65227#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65227\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65227\",\"name\":\"Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-13T15:39:07+00:00\",\"dateModified\":\"2026-05-13T15:39:08+00:00\",\"description\":\"Shanghai Immunocan Biotech Co., Ltd. announced the successful completion of a RMB 250 million (USD 36.8 million) Series A financing round led by Vivo Capital, with participation from Gold Mine Multi Family Office and existing shareholders Kingray Capital and TigerYeah Capital.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65227#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65227\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65227#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Immunocan Biotech Co., Ltd. announced the successful completion of a RMB 250 million (USD 36.8 million) Series A financing round led by Vivo Capital, with participation from Gold Mine Multi Family Office and existing shareholders Kingray Capital and TigerYeah Capital.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65227","og_locale":"en_US","og_type":"article","og_title":"Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms","og_description":"Shanghai Immunocan Biotech Co., Ltd. announced the successful completion of a RMB 250 million (USD 36.8 million) Series A financing round led by Vivo Capital, with participation from Gold Mine Multi Family Office and existing shareholders Kingray Capital and TigerYeah Capital.","og_url":"https:\/\/flcube.com\/?p=65227","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-13T15:39:07+00:00","article_modified_time":"2026-05-13T15:39:08+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65227#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65227"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms","datePublished":"2026-05-13T15:39:07+00:00","dateModified":"2026-05-13T15:39:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65227"},"wordCount":552,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Immunocan Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65227#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65227","url":"https:\/\/flcube.com\/?p=65227","name":"Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-13T15:39:07+00:00","dateModified":"2026-05-13T15:39:08+00:00","description":"Shanghai Immunocan Biotech Co., Ltd. announced the successful completion of a RMB 250 million (USD 36.8 million) Series A financing round led by Vivo Capital, with participation from Gold Mine Multi Family Office and existing shareholders Kingray Capital and TigerYeah Capital.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65227#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65227"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65227#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65227"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65227\/revisions"}],"predecessor-version":[{"id":65229,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65227\/revisions\/65229"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}